Kepos Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Kepos Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-72,211	Closed	-$420K	–	170
2019 Q4	$420K	Buy	72,211 +38,910	+117%	+$225K	0.04%	246
2019 Q3	$175K	Hold	33,301	–	–	0.02%	277
2019 Q2	$200K	Hold	33,301	–	–	0.02%	278
2019 Q1	$301K	Sell	33,301 -66,699	-67%	-$567K	0.02%	302
2018 Q4	$830K	Sell	100,000 -88,850	-47%	-$910K	0.06%	224
2018 Q3	$2.61M	Hold	188,850	–	–	0.13%	143
2018 Q2	$1.5M	Buy	+188,850	New	+$1.51M	0.08%	190

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Kepos Capital's ALDX Position: Q1 2020 in Review

Kepos Capital sold out of Aldeyra Therapeutics (ALDX) in Q1 2020, closing a stake of 72,211 shares — an estimated $420K sold.

Kepos Capital first reported a position in ALDX in Q2 2018 and held it in 7 quarters. The position peaked at $2.61M in Q3 2018. 72 funds tracked by Wall St. Rank hold ALDX as of Q1 2020.

Kepos Capital reported no remaining Aldeyra Therapeutics position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 72,211 Aldeyra Therapeutics shares in Q1 2020, an estimated $420K.
Kepos Capital first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 7 quarters.
Kepos Capital's Aldeyra Therapeutics position peaked at $2.61M in Q3 2018.
72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.